Insight Molecular Diagnostics Inc. — Director's Dealing 2021

Jun 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-06-24

Reporting Person: Last Andrew J. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-24	Option to Purchase Common Stock	$5.46	A	45000	Acquired	2031-06-23	Common Stock (45000)	Direct
2021-06-24	Restricted Stock Units	$0	A	10000	Acquired	2022-06-24	Common Stock (10000)	Direct

Footnotes

F1: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

F2: The Restricted Stock Units shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.